Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News PaxMedica Inc PXMD

PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral... see more

Recent & Breaking News (GREY:PXMD)

PaxMedica to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference

GlobeNewswire November 22, 2022

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

GlobeNewswire November 17, 2022

PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 15, 2022

PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission

GlobeNewswire November 8, 2022

PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

GlobeNewswire October 24, 2022

PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors

GlobeNewswire October 3, 2022

Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc.

ACCESS Newswire August 26, 2022